A Janus kinase inhibitor, JAB, is an interferon-γ-inducible gene and confers resistance to interferons

Blood

Volumn 92, Issue 5, 1998, Pages 1668-1676

  Sakamoto, Hiroshi ^b   Yasukawa, Hideo ^b   Masuhara, Masaaki ^b   Tanimura, Shyu ^b   Sasaki, Atsuo ^b   Yuge, Kentaro ^b   Ohtsubo, Motoaki ^b   Ohtsuka, Akira ^b   Fujita, Takasi ^b   Ohta, Tsunetaka ^b   Furukawa, Yusuke ^b   Iwase, Satsuki ^b   Yamada, Hisashi ^b   Yoshimura, Akihiko ^a  

^a KURUME UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; SIGNAL TRANSDUCTION;

EID: 0032170490     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.5.1668.417k09_1668_1676     Document Type: Article

References (33)

1. Darnell JE Jr, Kerr IM, Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415, 1994
2. Darnell JE Jr: STATs and Gene Regulation. Science 277:1630, 1997
3. Ihle JN: STATs: Signal transducers and activators of transcription. Cell 84:331, 1996
4. Mandelli F, Arcese W, Avvisati G: The interferons in haematological malignancies. Clin Haematol 7:91, 1994
5. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MH, Hersey P, Tam ND, Edmondson S, Devenish RJ, Ralph SJ: Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3γ. J Biol Chem 272:28779, 1996
6. Ohta T, Ando O, Kurimoto M: Establishment of new interferon-γ-resistant mutant cells with dominant phenotypes. J Interferon Cytokine Res 15:153, 1995
7. Klingmuller U, Bergelson S, Hsiao JG, Lodish HF: Multiple tyrosine residues in the cytosolic domain of the erythropoietin receptor promote activation of STAT5. Proc Natl Acad Sci USA93:8324, 1996
8. Kim TK, Maniatis T: Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 273:1717, 1996
9. Strous GJ, von Kerkhof P, Govers R, Ciechanover A, Schwartz AL: The ubiquifin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor. EMBO J 15:3806, 1996
10. Haspel RL, Salditt-Georfieff M, Darnell JE Jr: The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. EMBO J 15:6262, 1996
11. Wang D, Stravopodis D, Teglund S, Kitazawa J, Ihle JN: Naturally occurring dominant negative variants of Stat5. Mol Cell Biol 16:6141, 1996
12. Azam M, Lee C, Strehlow I, Schindler C: Functionally distinct isoforms of STAT5 are generated by protein processing. Immunity 6:691, 1997
13. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K: Specific inhibition of Stat3 signal transduction by PIAS3. Science 278:1803, 1997
14. Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Hara T, Miyajima A: A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 14:2816, 1995
15. Matsumoto A, Masuhara M, Mitsui K, Ohtsubo M, Miyajima A, Yoshimura A: CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89:3148, 1997
16. Endo AT, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanekura Y, Komiya S, Yoshimura A: A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387:921, 1997
17. Masuhara M, Sakamoto H, Matsumoto A, Suzuki R, Yasukawa H, Mitsui K, Wakioka T, Tanimura S, Sasaki A, Misawa H, Yokouchi M, Ohtsubo M, Yoshimura A: Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun 239:439, 1997
18. Starr R, Willson TA, Viney EM, Murray LJL, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ: A family of cytokine-inducible inhibitors of signaling. Nature 387:917, 1997
19. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S, Kishimoto T: Structure and function of a new STAT-induced STAT inhibitor. Nature 387:924, 1997
20. Minamoto S, Ikegame K, Ueno K, Narazaki M, Naka T, Yamamoto H, Matsumoto T, Saito H, Hosoe S, Kishimoto T: Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. Biochem Biophys Res Commun 237:79, 1997
21. Fujii H, Nakagawa Y, Schindler U, Kawahara A, Mori H, Gouilleux F, Groner B, Ihle JN, Minami Y, Miyazaki T, Taniguchi T: Activation of Stat5 by interleukin 2 requires a carboxyl-terminal region of the interleukin 2 receptor beta chain but is not essential for the proliferative signal transmission. Proc Natl Acad Sci USA 92:5482, 1995
22. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kikuchi N, Kitaoka T, Fukuda T, Hibi M, Hirano T: A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 15:3651, 1996
23. Yoshimura A, D'Andrea AD, Lodish HF: Friend spleen focus-forming virus glycoprotein gp55 interacts with the erythropoietin receptor in the endoplasmic reticulum and affects receptor metabolism. Proc Natl Acad Sci USA 87:4239, 1990
24. Schluter G, Celik A, Obata R, Schlicker M, Hofferbert S, Schlung A, Adham IM, Engel W: Sequence analysis of the conserved protamine gene cluster shows that it contains a fourth expressed gene. Mol Reprod Dev 43:1, 1996
25. Fukunaga R, Ishizaka-Ikeda E, Pan CX, Seto Y, Nagata S: Functional domains of the granulocyte colony-stimulating factor receptor. EMBO J 10:2855, 1991
26. Yamamura Y, Kageyama Y, Matuzaki T, Noda M, Ikawa Y: Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor. EMBO J 11:4909, 1992
27. Wakao H, Harada N, Kitamura T, Mui AL-F, Miyajima A: Interleukin 2 (IL2) and erythropoietin (EPO) activate STAT5/MGF via distinct pathways. EMBO J 14:2527, 1995
28. Yamanaka Y, Nakajima K, Fukada T, Hibi M, Hirano T: Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. EMBO J 15:1557, 1996
29. Pine R, Canova A, Schindler C: Tyrosine phosphorylated p91 binds to a single element in the ISGF2/IRF-1 promoter to mediate induction by IFN alpha and IFN gamma, and is likely to autoregulate the p91 gene. EMBO J 13:158, 1994
30. Ralph SJ, Wines BD, Payne MJ, Grubb D, Hatzinisiriou I, Linnane AW, Devenish RJ: Resistance of melanoma cell lines to interferons correlates with reduction of IFN-induced tyrosine phosphorylation. J Immunol 154:2248, 1995
31. Xu L, Rothman P: IFN-γ represses ∈ germline transcription and subsequently down-regulates switch recombination to ∈. Int Immunol 6:515, 1994
32. Wang ZE, Reiner SL, Zheng S, Dalton DK, Locksley RM: CD4 + effector cells default to the Th2 pathway in interferon gamma-deficient mice infected with Leishmania major. J Exp Med 179:1367, 1994
33. Pernis A, Gupta S, Gollob KJ, Garfein E, Coffman RL, Schindler C, Rothman P: Lack of interferon gamma receptor beta chain and the prevention of interferon gamma signaling in TH1 cells. Science 269:245, 1995